Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 11,653,213 | $1,545,798,768 | +4% | 0.67% |
| 2. | Diamond Hill Capital Ric Dillon | 6,073,765 | $805,684,927 | -8% | 3.69% |
| 3. | 2,172,000 | $288,115,800 | -30% | 0.05% | |
| 4. | Sessa Capital John Petry | 1,806,988 | $239,696,958 | -55% | 9.35% |
| 5. | AQR Capital Management Cliff Asness | 1,716,693 | $227,118,470 | +15% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing | |
| $138.17 | 949 | $131,123.33 | 74,381 | 2025-03-03 | Filing | |
| $138.17 | 562 | $77,651.54 | 31,970 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 169,823,136 | $22,527,038,990 | 0.41% | |
| 2. | 136,977,160 | $18,170,020,263 | 0.38% | |
| 3. | 77,664,753 | $10,302,229,485 | 0.42% | |
| 4. | 66,824,002 | $8,862,713,306 | 1.74% | |
| 5. | 50,734,446 | $6,729,881,607 | 1.46% |
News See All
Early Retirement Portfolio: Top 15 Stock Picks
The Fed predicted two-quarter-percentage-point decreases this year at its most recent statement in March, which is consistent with current market pricing.
Leerink Partners Begins Coverage on ABT
The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%.
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc.
10 Best Stocks to Buy For Beginners Now
On June 12, Dan Niles, Niles Investment Management founder and portfolio manager, joined CNBC's 'Squawk Box' to discuss the state of the economy and how he expects the market to catch up to reality later...
Jim Cramer Calls Abbott “Really Excellent”
Abbott Laboratories (NYSE:ABT) is one of the 17 stocks that Jim Cramer commented on.
Jim Cramer Commented on These 17 Stocks
On Friday, Mad Money host Jim Cramer shared his evolving view of Elon Musk’s company as he provided both praise and caution in light of recent developments involving Musk and President Donald Trump.
Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio
Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, the first device of its kind approved in the US to treat mitral ...
Abbott Laboratories (ABT) was up 16% in Q1
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Was Jim Cramer Right About Abbott Laboratories (ABT)?
We recently published a list of Jim Cramer Nailed These 11 Stock Predictions.